Biovertis AG (Vienna, Austria) is a clinical–stage pharmaceutical company. Through its 100% subsidiary Morphochem AG, Biovertis develops small-molecule drugs against multidrug-resistant pathogens.
Morphochem AG (Munich, Germany) is currently developing its proprietary novel Gram-positive antibacterial MCB3837/MCB3681 as an innovative intravenous treatment for Clostridium difficile infection (CDI).